XML 22 R34.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Assets and Liabilities Measured at Fair Value (Tables)
12 Months Ended
Dec. 31, 2019
Fair Value Disclosures [Abstract]  
Summary of Assets and Liabilities Subject to Fair Value Measurements
A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2019 are identified in the following table:
(in thousands)
 
Level 2
 
Total
Assets:
 
 
 
 
Commercial paper
 
$
73,710

 
$
73,710

Asset-back securities
 
77,810

 
77,810

Corporate debt securities
 
145,991

 
145,991

U.S. Government Agency Bonds
 
11,991

 
11,991

Money market funds
 
4,768

 
4,768

 
 
$
314,270

 
$
314,270

(in thousands)
 
Level 2
 
Level 3
 
Total
Liabilities:
 
 
 
 
 
 
Contingent consideration payable
 
$

 
$
22,681

 
$
22,681

Deferred compensation plan liability
 
4,419

 

 
4,419

 
 
$
4,419

 
$
22,681

 
$
27,100

A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2018 are identified in the following table:
(in thousands)
 
Level 2
 
Total
Assets:
 
 
 
 
Commercial paper
 
$
115,141

 
$
115,141

Asset-back securities
 
68,135

 
68,135

Corporate debt securities
 
240,726

 
240,726

Money market funds
 
3,082

 
3,082

 
 
$
427,084

 
$
427,084

(in thousands)
 
Level 2
 
Level 3
 
Total
Liabilities:
 
 
 
 
 
 
Contingent consideration payable
 
$

 
$
19,700

 
$
19,700

Deferred compensation plan liability
 
2,732

 

 
2,732

 
 
$
2,732

 
$
19,700

 
$
22,432


Schedule of Significant Unobservable Inputs Used in the Valuation of the Contingent Consideration Payable
The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB-200 Pompe program:
Contingent Consideration Liability
 
Fair value as of December 31, 2019
 
Valuation Technique
 
Unobservable Input
 
Range
 
 
(in thousands)
 
 
 
 
 
 
 
 
 
 
 
 
Discount rate
 
9.6%
Clinical and regulatory milestones
 
$
22,390

 
Probability weighted discounted cash flow
 
Probability of achievement of milestones
 
75% - 78%
 
 
 
 
 
 
Projected year of payments
 
2021 - 2022

Schedule of Changes in Contingent Consideration Payable
The following table shows the change in the balance of contingent consideration payable for the year ended December 31, 2019 and 2018, respectively:
 
 
Year ended December 31,
(in thousands)
 
2019
 
2018
Balance, beginning of the period
 
$
19,700

 
$
25,400

Milestones payable, included in accrued expenses
 

 
(9,000
)
Changes in fair value during the period, included in the Consolidated Statements of Operations
 
3,297

 
3,300

Adjustment for contingent consideration paid in stock
 
(316
)
 

Balance, end of the period
 
$
22,681

 
$
19,700